In January 2019, the FDA announced its plans to enhance the Sentinel Initiative through the use of emerging technologies and innovations in data science. Specifically, there are 5 strategic goals that have been laid out as part of this enhancement process, and notably for our Week 5 discussion topic, the augmentation of its safety analysis capabilities , and the use of the system to accelerate access to and broaden the use of real world data for real world evidence are two of those strategies. Do you think that these particular goals would address the type of criticism that has been directed to the Sentinel Initiative since its implementation? Why or why not?